Author's response to reviews

Title: Patan Hospital Experience In Treating Philadelphia Chromosome/BCR-ABL1 Positive Chronic Myeloid Leukemia Patients With Gleevec (Imatinib Mesylate); The First Generation Specific Tyrosine Kinase Inhibitor.

Authors:

Gyan K Kayastha (kayasthaogk@hotmail.com)
Padma Gurung (rinsey@yahoo.com)
Paras K Acharya (acharyaparas@hotmail.com)
Buddhi P Paudyal (buddhipaudyal@yahoo.com)
Bruce Hayes (blhayes@cms.org.au)
Mark Zimmerman (markz@wlink.com.np)
Arjun Karki (drakarki@pahs.edu.np)
Aaron S Mansfield (mansfield.aaron@mayo.edu)

Version: 5 Date: 25 November 2010

Author's response to reviews:

The affiliation for Aaron Mansfield was modified. One section of the introduction was changed to read "ethnic groups" instead of "ethnic and racial groups". One section of the discussion was changed when we listed the response of our patients to imatinib for grammatical purposes.